A new drug candidate targeting E. coli in the gut is in phase 1 clinical trials. According to a new paper it may improve the well-being of blood cancer patients and reduce their mortality rate from E. coli infections.
A new drug candidate targeting E. coli in the gut is in phase 1 clinical trials. According to a new paper it may improve the well-being of blood cancer patients and reduce their mortality rate from E. coli infections.
Contact us if you’re ready to make the transformational changes that will launch your business into hypergrowth.